1002-OR: Expanding the Target Space for DKD: A Multiplexed Characterization of AAV Cellular Tropism Targeting Tubular Epithelial Cells for High Throughput In Vivo Perturb-seq
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-1002-or ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von GAVIN PHARAOH und 18 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: In vivo modeling is essential to capture the dysregulated multicellular circuits driving DKD, but is limited by low throughput discovery. To identify causal drivers of DKD, we developed a multiplexed, in vivo pooled perturbation approach targeting tubular epithelial cells combined with single cell/nucleus RNAseq to link genetic perturbations to disease pathology.
Methods
12 individual single stranded (ss) AAV serotypes were packaged with barcoded DNA pools under pol3 promoter expressing a fluorescent reporter (ITR-Promoter-mGreenLantern-Sv40(polyA)-Pol3-Barcode-ITR) and pooled equimolarly. This library was administered IV into hamsters with insulin resistance or a rat model of 5/6 nephrectomy. Two weeks post-injection, GFP-positive nuclei were isolated and analyzed via snRNA-seq to map viral uptake to specific kidney cell types.
Results
We identified three serotypes, AAV-KP1, AAV-DJ, and AAV-DJ9 that preferentially transduced proximal tubule epithelial cells (PTEC), specifically the injury vulnerable S3 segment (PT-S3). Notably, AAV-DJ and AAVD-J9 demonstrated ~7-fold higher selectivity for PTECs compared to AAV-KP1, a commonly used serotype previously validated in literature to target PTECs using localized delivery. Conversely, AAV-KP1 barcodes were significantly enriched in endothelial cells, a tropism not observed with other serotypes.
Conclusion
In conclusion, our multiplexed RNA-barcoded screening platform successfully identifies serotypes that preferentially target and express in epithelial and/or endothelial cells, active drivers of kidney disease progression. These findings provide a critical toolbox for future high-throughput perturbation screens, enabling the interrogation of causal relationships between genetic signatures and DKD progression in vivo at scale. Disclosure G. Pharaoh: None. J. Nonora: None. D. Shao: None. C. Le: None. A. Gupta: None. C. Carrico: None. J. Chen: None. S. Shambhu: None. I. Driver: Stock/Shareholder; Current; AbbVie Inc., Amgen Inc. A. Lim: None. V. Kartha: None. C.Q. Bowman: None. L. Chio: None. L. Fung: None. K. Fagan: None. D. Popov: None. C. Towne: None. J. Hsieh: None. M.B. Jensen: None.
Zitieren
APA
PHARAOH, G., NONORA, J., SHAO, D., LE, C., GUPTA, A., CARRICO, C., CHEN, J., SHAMBHU, S., DRIVER, I., LIM, A., KARTHA, V., BOWMAN, C. Q., CHIO, L., FUNG, L., FAGAN, K., POPOV, D., TOWNE, C., HSIEH, J., & JENSEN, M. B. (2026). 1002-OR: Expanding the Target Space for DKD: A Multiplexed Characterization of AAV Cellular Tropism Targeting Tubular Epithelial Cells for High Throughput In Vivo Perturb-seq. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-1002-or
Vancouver
PHARAOH G, NONORA J, SHAO D, LE C, GUPTA A, CARRICO C, et al. 1002-OR: Expanding the Target Space for DKD: A Multiplexed Characterization of AAV Cellular Tropism Targeting Tubular Epithelial Cells for High Throughput In Vivo Perturb-seq. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-1002-or
BibTeX
@article{PHARAOH2026,
author = {PHARAOH, GAVIN and NONORA, JESI and SHAO, DAN and LE, CARMEN and GUPTA, ARNAV and CARRICO, CHRIS and CHEN, JINGSHU and SHAMBHU, SMITHA and DRIVER, IAN and LIM, AMBER and KARTHA, VINAY and BOWMAN, CHASE Q. and CHIO, LINDA and FUNG, LIANNA and FAGAN, KELLY and POPOV, DIMITRY and TOWNE, CHRIS and HSIEH, JOANNE and JENSEN, MARTIN B.},
title = {1002-OR: Expanding the Target Space for DKD: A Multiplexed Characterization of AAV Cellular Tropism Targeting Tubular Epithelial Cells for High Throughput In Vivo Perturb-seq},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-1002-or}
}
EUVIMED